• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    WNS Announces Addition of Tim Main to Board of Directors

    5/18/21 4:15:00 PM ET
    $WNS
    $DGX
    $JBL
    $SHAC
    Real Estate
    Real Estate
    Medical Specialities
    Health Care
    Get the next $WNS alert in real time by email

    WNS (Holdings) Limited (NYSE:WNS), a leading provider of global Business Process Management (BPM) solutions, today announced the appointment of Timothy L. Main to the company's Board of Directors effective June 1, 2021. Tim has spent his entire career in a B2B services/outsourcing environment, including more than 25 years with Jabil, Inc. (NYSE:JBL), a leading provider of manufacturing services with a global operational footprint. At Jabil, Tim worked his way from a Production Control Manager position to eventually serve as President, Chief Executive Officer, and Chairman of the Board. During his 13-year tenure as Chief Executive Officer of Jabil, he led the company's transformation and growth to a $17+ billion, 100,000 employee organization through organic growth and strategic acquisitions. Tim is currently non-executive Chairman of the Board of Directors and a member of the Cyber Committee at Jabil. In addition, he serves on the Board of Quest Diagnostics (NYSE:DGX) as Chair of the Cybersecurity Committee and a member of the Audit & Finance and Governance committees, and on the Board of SCP & CO Healthcare Acquisition Co. (NASDAQ:SHAC), where he serves as a member of the Audit & Finance Committee.

    "Tim is a proven leader with a distinguished track record in international operations, corporate governance, vision and strategy, and technology-led growth," said Adrian T. Dillon, WNS's Chairman of the Board. "We are pleased to welcome Tim to the WNS Board of Directors, and believe that his experience guiding large organizations and developing talent will be a tremendous asset to the company."

    "The WNS team is delighted to add an experienced executive like Tim to our Board," said Keshav R. Murugesh, Chief Executive Officer of WNS. "His background in leading high-performing teams, driving both organic and inorganic revenue growth, and managing global operations will help WNS continue to generate exceptional value for all of our key stakeholders."

    About WNS

    WNS (Holdings) Limited (NYSE:WNS) is a leading Business Process Management (BPM) company. WNS combines deep industry knowledge with technology, analytics and process expertise to co-create innovative, digitally led transformational solutions with over 375 clients across various industries. WNS delivers an entire spectrum of BPM solutions including industry-specific offerings, customer interaction services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of March 31, 2021, WNS had 43,997 professionals across 58 delivery centers worldwide including facilities in Australia, China, Costa Rica, India, the Philippines, Poland, Romania, South Africa, Spain, Sri Lanka, Turkey, the United Kingdom, and the United States. For more information, visit www.wns.com.

    Safe Harbor Provision

    This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 20-F and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210518006071/en/

    Get the next $WNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WNS
    $DGX
    $JBL
    $SHAC

    CompanyDatePrice TargetRatingAnalyst
    Jabil Inc.
    $JBL
    3/12/2026$275.00Outperform
    Robert W. Baird
    Quest Diagnostics Incorporated
    $DGX
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    Quest Diagnostics Incorporated
    $DGX
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    WNS (Holdings) Limited
    $WNS
    7/17/2025Hold
    Deutsche Bank
    Jabil Inc.
    $JBL
    7/2/2025$245.00Buy
    Stifel
    Jabil Inc.
    $JBL
    6/18/2025Hold → Buy
    Argus
    Quest Diagnostics Incorporated
    $DGX
    4/2/2025$195.00Buy
    Redburn Atlantic
    Quest Diagnostics Incorporated
    $DGX
    3/4/2025$185.00Buy → Neutral
    Citigroup
    More analyst ratings

    $WNS
    $DGX
    $JBL
    $SHAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Jabil with a new price target

    Robert W. Baird initiated coverage of Jabil with a rating of Outperform and set a new price target of $275.00

    3/12/26 8:53:39 AM ET
    $JBL
    Electrical Products
    Technology

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    $WNS
    $DGX
    $JBL
    $SHAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

    SECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director. Including Mr. Wentworth, the company's board has eleven members. "As a former CEO of several large, publicly traded healthcare organizations, Tim brings incredible leadership experience to the Quest board," said Jim Davis, chairman, CEO and president of Quest Diagnostics. "His depth in the many chan

    3/12/26 4:07:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Jabil's Second Quarter of Fiscal Year 2026 Earnings Announcement Set

    Jabil Inc. (NYSE:JBL) today announced it will release its second quarter of fiscal year 2026 financials on Wednesday, March 18, 2026, before the market opens. The company will host a conference call and webcast to review the results. What: Jabil's Second Quarter of Fiscal Year 2026 Conference Call and Webcast When: Wednesday, March 18, 2026 – 8:30 a.m. ET Dial-in: U.S. (877) 407-6184 or International (201) 389-0877 To access the live audio webcast and the accompanying slide presentation, visit the Investor Relations section of Jabil's website, located at https://investors.jabil.com. An archived replay of the webcast will be available after completion of the call. About Jabil:

    3/4/26 4:15:00 PM ET
    $JBL
    Electrical Products
    Technology

    Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

    New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risksSECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider.  Available now to all adult users of the company's secure, free patient mobile app and portal MyQuest, individuals can enga

    3/2/26 9:02:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $WNS
    $DGX
    $JBL
    $SHAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Quest Diagnostics Incorporated

    3 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    3/11/26 6:03:47 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Quest Diagnostics Incorporated

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    3/11/26 6:05:01 PM ET
    $DGX
    Medical Specialities
    Health Care

    Executive Vice President & CFO Samad Sam was granted 13,947 shares and covered exercise/tax liability with 7,720 shares, increasing direct ownership by 23% to 33,268 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    3/6/26 4:45:16 PM ET
    $DGX
    Medical Specialities
    Health Care

    $WNS
    $DGX
    $JBL
    $SHAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Chintapalli Anil bought $1,115,226 worth of shares (20,000 units at $55.76), increasing direct ownership by 72% to 47,900 units (SEC Form 4)

    4 - WNS (HOLDINGS) LTD (0001356570) (Issuer)

    6/2/25 4:41:04 PM ET
    $WNS
    Real Estate

    $WNS
    $DGX
    $JBL
    $SHAC
    SEC Filings

    View All

    Quest Diagnostics Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    3/12/26 4:30:56 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    3/2/26 2:21:02 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Quest Diagnostics Incorporated

    10-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/26/26 4:38:46 PM ET
    $DGX
    Medical Specialities
    Health Care

    $WNS
    $DGX
    $JBL
    $SHAC
    Financials

    Live finance-specific insights

    View All

    Jabil's Second Quarter of Fiscal Year 2026 Earnings Announcement Set

    Jabil Inc. (NYSE:JBL) today announced it will release its second quarter of fiscal year 2026 financials on Wednesday, March 18, 2026, before the market opens. The company will host a conference call and webcast to review the results. What: Jabil's Second Quarter of Fiscal Year 2026 Conference Call and Webcast When: Wednesday, March 18, 2026 – 8:30 a.m. ET Dial-in: U.S. (877) 407-6184 or International (201) 389-0877 To access the live audio webcast and the accompanying slide presentation, visit the Investor Relations section of Jabil's website, located at https://investors.jabil.com. An archived replay of the webcast will be available after completion of the call. About Jabil:

    3/4/26 4:15:00 PM ET
    $JBL
    Electrical Products
    Technology

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $WNS
    $DGX
    $JBL
    $SHAC
    Leadership Updates

    Live Leadership Updates

    View All

    Jabil Announces Appointment of New Chairman, Directors to the Board

    Jabil Inc. (NYSE:JBL), a global engineering, supply chain, and manufacturing solutions provider, today announced that Steve Raymund has been appointed Chairman of its Board of Directors. Additionally, Thomas T. Edman and Raejeanne Skillern have been appointed to its Board of Directors. "I am honored to accept this role and look forward to collaborating with the rest of the Board to continue advancing Jabil's strategic direction," said Raymund. "We are also pleased to welcome Tom and Raejeanne to our Board. Tom's leadership in electronics manufacturing paired with Raejeanne's experience in key growth industries like cloud and data centers will be terrific additions to Jabil." Mr. Raymund

    1/22/26 4:15:00 PM ET
    $JBL
    Electrical Products
    Technology

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $WNS
    $DGX
    $JBL
    $SHAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jabil Inc.

    SC 13G/A - JABIL INC (0000898293) (Subject)

    11/12/24 10:32:13 AM ET
    $JBL
    Electrical Products
    Technology

    Amendment: SEC Form SC 13G/A filed by WNS (Holdings) Limited

    SC 13G/A - WNS (HOLDINGS) LTD (0001356570) (Subject)

    11/1/24 4:27:50 PM ET
    $WNS
    Real Estate

    Amendment: SEC Form SC 13G/A filed by WNS (Holdings) Limited

    SC 13G/A - WNS (HOLDINGS) LTD (0001356570) (Subject)

    7/10/24 10:10:34 AM ET
    $WNS
    Real Estate